SALMEDIX
Salmedix is an oncology drug development company with a commercial focus on the treatment of hematologic malignancies, or blood cancers. Its primary product, SDX-105, is marketed by healthcare professionals in Germany for the treatment of several types of blood cancers. Salmedix conducts Phase II clinical trials for SDX-105 in the U.S. and Canada. Its other clinical-stage product candidates, SDX-101 and SDX-102, each with significant prior human clinical experience, are also in Phase II development. Founded in 2000 by David Kabakoff, Salmedix is headquartered in San Diego, California.
SALMEDIX
Industry:
Biotechnology Health Care Medical
Founded:
2000-11-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.salmedix.com
Total Employee:
11+
Status:
Closed
Total Funding:
72.5 M USD
Similar Organizations
Kinnate Biopharma
Kinnate Biopharma develops precision oncology therapeutics to treat patients with genomically-defined cancers.
Founder
Investors List
OrbiMed
OrbiMed investment in Series C - Salmedix
H.I.G. Capital
H.I.G. Capital investment in Series C - Salmedix
Cariden Technologies
Cariden Technologies investment in Series C - Salmedix
Covera Ventures
Covera Ventures investment in Series C - Salmedix
Novo Holdings
Novo Holdings investment in Series C - Salmedix
Quilvest Capital Partners
Quilvest Capital Partners investment in Series C - Salmedix
Delphi Ventures
Delphi Ventures investment in Series B - Salmedix
InterWest Partners
InterWest Partners investment in Series B - Salmedix
Aberdare Ventures
Aberdare Ventures investment in Series B - Salmedix
Alexandria Real Estate Equities
Alexandria Real Estate Equities investment in Series B - Salmedix
